1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow BOE Technology Group Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy - NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | BOE Technology Group Co., Ltd. | 42 | 2026-08-01 | 2026-08-26 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1)
Bevacizumab (1) · Capecitabine (1) · Cetuximab (1) · Pemetrexed (1) · S 1 (combination) (1)